NEW YORK (GenomeWeb News) – Exagen Diagnostics today said that New York has approved its Avise SLE diagnostic, SLE-Systemic Lupus Erythematosus.
The Albuquerque, NM-based firm said that its Avise SLE brand is now available for lupus and connective tissue disease patients across the US. Exagen, which raised $5.3 million last month, runs its CLIA-certified laboratory in Vista, Calif.
Avise SLE is a blood-based test comprising five biomarkers used for ruling in lupus and ruling out other rheumatic diseases. Exagen also offers Avise SLE+ Connective Tissue, a test for helping in the differential diagnosis of autoimmune diseases.
Together, they provide a 19-marker diagnostic that offers greater sensitivity and specificity than methods based on standard antinuclear antibodies and double stranded DNA, the company said.